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Background and aim
While only 10-30% of patients treated with currently
approved single immunotherapies demonstrate long-
term benefit, treatment efficacy in responders correlates
with increased CD8+ T cell responses to neoantigens
(tumor antigens hidden from the immune system). Thus,
to improve presentation of tumor antigens and expose
neoantigens we engineered a single-step nanoparticle
antigen presentation system (SNAPS) that enables both
membrane and cytosolic cancer proteins to be covalently
coupled to an injectable nanoparticle emulsion.
Methods
B16 melanoma (SNAPS-B16), primary melanocyte
(SNAPS-MEL), 4T1 breast cancer (SNAPS-4T1) lysate or
mouse IgG (SNAPS-C) were used for coating polystyrene
nanoparticles via an EDAC linker. One day or 11 days
post B16-F10 tumor cell challenge (100,000 cells, intra-
dermal, right flank), mice were treated (at the same site
as the tumor cell injection) with 200 μL of 1% w/v cell
lysate coated nanoparticles. Tumors were measured
using calipers every 2-3 days. Flow cytometry staining
was performed for antigen presenting cells (APCs) and
CD8+ T cells after dissection and mechanical dissocia-
tion of the tumor. Statistical analyses were performed
using the student t test and Prism v4.0 software (Graph-
Pad). Differences with a P < 0.05 were considered statisti-
cally significant.
Results
We observed that SNAPS-B16 delivered at one day post
tumor challenge significantly reduced tumor growth (P <
0.01) compared to SNAPS-C (which had no effect).
SNAPS delivered at day 11 (when tumors were approxi-
mately 5 mm × 5 mm) significantly halted tumor growth
(< 2-fold increase over the course of 10 days) while B16
treated with SNAPS-C increased ~16-fold (P < 0.01).
Neither SNAPS-4T1 nor SNAPS-MEL had any effect on
the growth of B16 in vivo, demonstrating the induction of
an antigen-specific anti-tumor response with SNAPS-B16.
Additionally, SNAPS-B16 significantly increased (P < 0.01)
the proportion of APCs within the tumor microenviron-
ment compared to the SNAPS-C, as evidenced by the
increased percentage of MHC-II+ cells).
Conclusions
Our results demonstrate that SNAPS coupling of whole
tumor lysate from cancer cells to nanoparticles delivers a
robust anti-tumor immune response resulting in enhanced
tumor regression. These findings demonstrate that a can-
cer-derived protein unique to B16 melanoma (rather than
to tumors in general or to normal melanocytes) coating
the SNAPS confers tumor specificity. Although prelimin-
ary, our reported innovation of using nanoparticles coated
through EDAC with tumor proteins in this specific man-
ner to elicit immune responses against tumor cells in vivo
may sidestep many of the complexities and per patient
costs associated with current cell-based immunotherapies
and tumor antigen sequencing.
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